Malvern, PA — Venatorx Pharmaceuticals announced that its President and CEO, Christopher J. Burns, Ph.D., will present at the UBS Global Healthcare Conference on Monday, May 21, 2018 at 8:00am ET in Ballroom V at the Grand Hyatt New York. The presentation will be webcast at

Dr. Burns will present attendees with an overview of Venatorx’s pipeline and its unique operating model of leveraging non-dilutive funding to maximize investor dollars.

About Venatorx Pharmaceuticals, Inc.

Led by a world-class team of pharmaceutical veterans, Venatorx is a private pharmaceutical company that is developing a new wave of antibiotic products to combat the increasing threat of carbapenem antibiotic resistance. Venatorx’s lead product, VNRX-5133, is an injectable broad-spectrum beta-lactamase inhibitor (BLI) that directly inhibits all four Ambler classes of beta-lactamases. Early clinical studies of cefepime/VNRX-5133 have been completed and Venatorx plans to start Phase 3 pivotal trials in the second half of 2018. In addition, Venatorx has a broad pipeline of preclinical programs, including a broad-spectrum orally bioavailable BLI, and a novel class of Penicillin-Binding Protein (PBP) inhibitors that are impervious to beta-lactamase-driven resistance. For more information, please visit